English (UK)
中文版杨 刚
Chengdu Jian River Pharmaceutical Co., Ltd. was established in 2019 with a registered capital of 20 million yuan. The establishment of jianRiver serves Sichuan Development (Holdings) Co., Ltd. and the people's Government of Pengzhou City to set up a "Pengzhou Fund". For Tianfu traditional Chinese Medicine City in the global recruitment and incubation of pharmaceutical projects, through docking funds to provide professional management and services to provide support for the growth of the project. As the main body of the construction and operation of the innovation incubator in Pengzhou Tianfu traditional Chinese Medicine City, relying on rich project channel resources and professional service team, it is committed to helping excellent modern Chinese medicine research and development enterprises, new drug research and development enterprises, cutting-edge biotechnology companies, medical device companies and large health industry related enterprises to accurately land in Pengzhou, through the whole industry chain services such as professional incubation acceleration, achievement transformation and financial investment. Promote the rapid development of innovative start-up enterprises. Adhering to the concept that "high-quality projects are the foundation of industrial development, and first-class talents are the core force of project growth", Jian River will gather high-quality projects to jointly build a high-quality medicine and large-scale health project incubation base in Pengzhou. Help more outstanding top entrepreneurial talents to realize their entrepreneurial ideals.
Chengdu Jian River Pharmaceutical Co., Ltd.
商务总监玉忠 化
license in innovative medicine and 505(b)(2),R&D generic drugs
Yatai institute of innovative medicine
商务VPNicky 吕
Founded in 2005, Baiyu is dedicated to R&D, manufacturing and marketing high-quality pharmaceutical products and APIs to all patients. As an innovation-based pharmaceutical company, we are specializing in chemical/botanical/biological medicinal products, especially ginkgo pharmaceutical products. And in 2020, aiming to protect everyone’s healthcare, Baiyu has built own subsidiary to produce high quality of Personal Protective Equipment to worldwide market.
With more than 1,300 employees and 8 wholly owned subsidiaries, Baiyu has a rich pipeline of products launched for neuropsychiatric, cardio-cerebrovascular, anti-tumor, respiratory, digestive, anti-infective areas along with many products under development. And Ginkgolide injection is the first innovative botanical injectable approved since the implementation of Drug Registration Regulation (2007), of which the active ingredient contents reach up to 99%.
Currently, several production lines have obtained GMP certificates, and new factories meeting EU&US GMP requirements with fully automatic and intelligent operations have been built to accelerate Baiyu’s globalization process.
With more than 1,300 employees and 8 wholly owned subsidiaries, Baiyu has a rich pipeline of products launched for neuropsychiatric, cardio-cerebrovascular, anti-tumor, respiratory, digestive, anti-infective areas along with many products under development. And Ginkgolide injection is the first innovative botanical injectable approved since the implementation of Drug Registration Regulation (2007), of which the active ingredient contents reach up to 99%.
Currently, several production lines have obtained GMP certificates, and new factories meeting EU&US GMP requirements with fully automatic and intelligent operations have been built to accelerate Baiyu’s globalization process.
Chengdu Baiyu Pharmaceutical Co.,Ltd
Lv文英 周
a stock company in China. Focus on the high quality finish product according to cGMP.
Responsive Web Design powered by 